GalNAc@PEG@siRNA-PLGA NCs validated superior anti-tumor effect with respect to free survivin siRNA which may be because of the following parameter viz., galactosylation of GalNAc to PLGA enhanced the cellular uptake and internalization of NC into hepatoma cells; PEGylation increased the accumulation of siRNA in tissue by prolonging the circulation time and reducing uptake by reticuloendothelial system. The gene discussed is BIRC5; the disease is hepatocellular carcinoma.